Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stopping versus continuing metformin around elective coronary angiography
IRCT20240821062831N1Phase 3Completed
- Sponsor
- International Research Center of Gilan University of Medical Sciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Research Center of Gilan University of Medical Sciences. Primary endpoints: Change in serum creatinine, Kidney function after angiography and 6 more. Started Sep 2024; status: completed.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20240821062831N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240821062831N1.